A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
Clinical Trial Grant
Administered By
Neurology
Awarded By
Neuraltus Pharmaceuticals, Inc
Start Date
August 1, 2016
End Date
October 10, 2018
Administered By
Neurology
Awarded By
Neuraltus Pharmaceuticals, Inc
Start Date
August 1, 2016
End Date
October 10, 2018